Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR
|
|
May 16, 2011 -- San Diego --
Volcano Corporation (NASDAQ: VOLC) today announced its participation
in the Paris course for Revascularization (EuroPCR) from May 17 -
20. Volcano's focus will be on highlighting the strength of its product
portfolio, which includes innovative devices like the Vascular Imaging
Balloon Catheter (VIBE® RX),
and its sponsorship of a symposium that highlights the use and value
of Precision Guided Therapy in clinical practice today.
"Volcano is excited to share our state-of-the-art intravascular therapy guidance and optimization solutions at this year's EuroPCR," commented Scott Huennekens, President and CEO of Volcano. "Globally,
clinicians are pleased about the insight our technologies provide them
so they can more precisely personalize the treatment of their patients."
Scientific Symposium on Precision Guided Therapy
Volcano is sponsoring a symposium designed to provide real world experiences
and novel techniques from key opinion leaders in interventional cardiology
from France, Poland, Italy, and the UK. "Precision Guided Therapy: Simple techniques to go beyond angiography in everyday practice" will
take place on Wednesday, May 18th, in Room 352AB in the Palais Des
Congres.
Product Innovations
Volcano will feature its suite of precision guided therapy technologies, which includes integrated cath lab systems, coronary and peripheral IVUS catheters, and physiology guide wires measuring both pressure and flow. These products, which are all available for sale in the U.S. and/or Europe, include:
- The PrimeWire PRESTIGE™, the next generation
Fractional Flow Reserve (FFR) wire with a familiar frontline tip, better
torque and more support
for challenging lesions;
- The Eagle Eye® Platinum, the #1 digital IVUS
catheter in the world, which provides exceptional deliverability, the
convenience of radiopaque markers, and three imaging modalities including
grayscale IVUS, VH® IVUS and ChromaFlo®;
- The VIBE® RX Vascular Imaging Balloon Catheter,
which can quickly access, prepare, and assess challenging lesions and
provide precise,
targeted balloon
dilatation with immediate confirmation of interventional results; and
- The s5™/s5i™ 3.2.1 software, which streamlines
the workflow for both IVUS and FFR procedures and is compatible with
more than 3,700 Volcano
systems installed worldwide.
Volcano plans to highlight progress in the development
of a prototype allowing the co-registration of IVUS images with angiography
in an automated fashion. This technology has the potential to disburden clinicians
from identifying the relationship between the angiographic image and the
IVUS information on non-registered data sets. "We are confident that the combination of two existing imaging modalities will ease the workflow for the physician during coronary interventions," continued
Huennekens.
All products will be available for demonstration at Booth #F29, Level 1. Volcano's technology will also be on display in other booths, including GE Healthcare, Siemens Healthcare, Philips Healthcare, and Toshiba Medical Systems. In addition, Volcano will highlight its extensive pipeline of imaging and therapy products still in development, including Optical Coherence Tomography (OCT), Micro Catheters, and Forward Looking Imaging.
Live Case Transmissions
Throughout EuroPCR, Volcano technology, including FFR, IVUS, Image-Guided Therapy, and Image Co-Registration, will be featured in live case transmissions from around the world.
About Volcano Corporation
Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Our products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information - using sound and light as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of the U.S. Private Securities Litigation Reform Act of 1995. Any statements
in this release that are not historical facts may be considered "forward-looking statements." Forward-looking
statements are based on management's current expectations and are subject
to risks and uncertainties which may cause Volcano's results to differ materially
and adversely from the statements contained herein. Some of the potential
risks and uncertainties that could cause actual results to differ include
the pace and extent of market adoption of the company's products and technologies,
growth strategies, timing and achievement of regulatory approvals, timing
and achievement of product development milestones, outcome of ongoing litigation,
the impact and benefits of market developments, dependence upon third parties,
product introductions, unexpected new data, safety and technical issues,
market conditions, and other risks inherent to medical device development
and commercialization. These and additional risks and uncertainties are more
fully described in Volcano's filings made with the Securities and Exchange
Commission, including our recent quarterly report on Form 10-Q. Undue reliance
should not be placed on forward-looking statements which speak only as of
the date they are made. Volcano disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances after the
date they are made, or to reflect the occurrence of unanticipated events.
Source: Volcano
Corporation
|